{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:52:29Z","timestamp":1776185549756,"version":"3.50.1"},"reference-count":39,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ANO \u2018Moscow Center for Innovative Healthcare Technologies\u2019"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Diffuse large B-cell lymphoma (DLBCL) is molecularly heterogeneous, and approximately 30-50% of patients fail to achieve cure with standard R-CHOP. Genotype-directed first-line therapy may improve outcomes by targeting subtype-specific oncogenic pathways. This study evaluated the feasibility, efficacy, and safety of a molecularly adapted R-CHOP-X strategy with two-year follow-up. Methods: In this single-center, prospective, non-randomized study conducted between September 2023 and the data cut-off (16 September 2025), 43 adults with newly diagnosed DLBCL (excluding high-grade B-cell lymphoma, primary immune-privileged, and primary mediastinal large B-cell lymphomas) underwent tumor genotyping using the LymphGen classification after targeted sequencing: a 19-gene Sanger panel (Cohort 1, n = 35) or an expanded 60-gene panel (Cohort 2, n = 8; proof-of-concept). All patients received one initial cycle of R-CHOP as bridge therapy pending molecular profiling results, followed by five cycles of R-CHOP-X, with the additional agent (vorinostat, acalabrutinib, decitabine, or lenalidomide) selected according to molecular subtype. Response was assessed by PET\/CT per Lugano criteria; adverse events were graded per NCI CTCAE v5.0. Results: The overall study population was predominantly high-risk: 72% had an IPI of 3\u20135, 58% had stage III\u2013IV disease, and 67% exhibited a non-GCB immunophenotype. Expansion from the 19-gene to the 60-gene panel reduced unclassifiable (NOS) cases from 34% to 12%. The overall response rate was 100% (43\/43); complete response among patients completing therapy was 100% (35\/35). At two years, overall survival was 92% (95% CI 83\u2013100%) and progression-free survival was 94% (95% CI 86\u2013100%). Two early relapses occurred (NOS and N1 subtypes), both resulting in death. Grade 3\u20134 neutropenia, thrombocytopenia, and anemia occurred in 26%, 12%, and 7% of patients, respectively; no dose reductions or treatment discontinuations were recorded. Conclusions: Molecularly adapted R-CHOP-X is feasible and associated with high response rates and favorable two-year survival in newly diagnosed DLBCL, comparing favorably with historical R-CHOP outcomes in high-risk populations. Expanded genomic panels substantially improve molecular classifiability. These findings warrant validation in larger, multicenter, randomized clinical trials.<\/jats:p>","DOI":"10.3390\/jcm15082983","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:47:02Z","timestamp":1776181622000},"page":"2983","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecularly Adapted Antitumor Therapy for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Two-Year Follow-Up Results"],"prefix":"10.3390","volume":"15","author":[{"given":"Marat","family":"Mingalimov","sequence":"first","affiliation":[{"name":"Moscow Clinical Science and Research Center 52, 123182 Moscow, Russia"},{"name":"Department of Hematology, I.M. Sechenov First Moscow State Medical University\u2014Ministry of Health of Russia (Sechenov University), 119991 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Baryakh","sequence":"additional","affiliation":[{"name":"Moscow Clinical Science and Research Center 52, 123182 Moscow, Russia"},{"name":"Department of Hematology, I.M. Sechenov First Moscow State Medical University\u2014Ministry of Health of Russia (Sechenov University), 119991 Moscow, Russia"},{"name":"FSBEI FPE \u00abRussian Medical Academy of Continuous Professional Education\u00bb of the Ministry of Healthcare of the Russian Federation, 125993 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey","family":"Misyurin","sequence":"additional","affiliation":[{"name":"N.I. Vavilov Institute of General Genetics, 119991 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Kesaeva","sequence":"additional","affiliation":[{"name":"LLC \u00abGenetechnology\u00bb, 117437 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasmik","family":"Mkrtchyan","sequence":"additional","affiliation":[{"name":"LLC \u00abGenetechnology\u00bb, 117437 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Misyurina","sequence":"additional","affiliation":[{"name":"Moscow Clinical Science and Research Center 52, 123182 Moscow, Russia"},{"name":"Department of Hematology, I.M. Sechenov First Moscow State Medical University\u2014Ministry of Health of Russia (Sechenov University), 119991 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariia","family":"Orlova","sequence":"additional","affiliation":[{"name":"Department of Hematology, I.M. Sechenov First Moscow State Medical University\u2014Ministry of Health of Russia (Sechenov University), 119991 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Tolstykh","sequence":"additional","affiliation":[{"name":"Moscow Clinical Science and Research Center 52, 123182 Moscow, Russia"},{"name":"Department of Hematology, I.M. Sechenov First Moscow State Medical University\u2014Ministry of Health of Russia (Sechenov University), 119991 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Zotina","sequence":"additional","affiliation":[{"name":"Moscow Clinical Science and Research Center 52, 123182 Moscow, Russia"},{"name":"Department of Hematology, I.M. Sechenov First Moscow State Medical University\u2014Ministry of Health of Russia (Sechenov University), 119991 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliia","family":"Shimanovskaia","sequence":"additional","affiliation":[{"name":"Moscow Clinical Science and Research Center 52, 123182 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8012-1640","authenticated-orcid":false,"given":"Tatiana","family":"Chudnova","sequence":"additional","affiliation":[{"name":"Moscow Clinical Science and Research Center 52, 123182 Moscow, Russia"},{"name":"Department of Hematology, I.M. Sechenov First Moscow State Medical University\u2014Ministry of Health of Russia (Sechenov University), 119991 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Ivanova","sequence":"additional","affiliation":[{"name":"Moscow Clinical Science and Research Center 52, 123182 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Kochneva","sequence":"additional","affiliation":[{"name":"Moscow Clinical Science and Research Center 52, 123182 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kseniya","family":"Tsurkina","sequence":"additional","affiliation":[{"name":"Moscow Clinical Science and Research Center 52, 123182 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8480-5505","authenticated-orcid":false,"given":"Dmitry","family":"Lebedev","sequence":"additional","affiliation":[{"name":"Moscow Clinical Science and Research Center 52, 123182 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgii","family":"Tyshkevich","sequence":"additional","affiliation":[{"name":"FSBI FPE \u00abCentral State Medical Academy\u00bb of the Administrative Department of the President of the Russian Federation, 121359 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Bekreneva","sequence":"additional","affiliation":[{"name":"Moscow Clinical Science and Research Center 52, 123182 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1653-8388","authenticated-orcid":false,"given":"Viktoriia","family":"Basova","sequence":"additional","affiliation":[{"name":"N.I. Vavilov Institute of General Genetics, 119991 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1757-4683","authenticated-orcid":false,"given":"Mikhail","family":"Donskoy","sequence":"additional","affiliation":[{"name":"JSC \u00abEuropean Medical Center\u00bb, 129110 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergej","family":"Rodnikov","sequence":"additional","affiliation":[{"name":"Moscow Clinical Science and Research Center 52, 123182 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6954-1564","authenticated-orcid":false,"given":"Ivan","family":"Abramov","sequence":"additional","affiliation":[{"name":"SBIH Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM Moscow, 111123 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Bodunova","sequence":"additional","affiliation":[{"name":"SBIH Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM Moscow, 111123 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saida","family":"Gadzhieva","sequence":"additional","affiliation":[{"name":"Moscow Healthcare Department, 43 Oruzheynyy Pereulok, 127006 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Semina","sequence":"additional","affiliation":[{"name":"Moscow Healthcare Department, 43 Oruzheynyy Pereulok, 127006 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey","family":"Andreev","sequence":"additional","affiliation":[{"name":"Moscow Clinical Science and Research Center 52, 123182 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inna","family":"Samsonova","sequence":"additional","affiliation":[{"name":"Moscow Clinical Science and Research Center 52, 123182 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Lysenko","sequence":"additional","affiliation":[{"name":"Moscow Clinical Science and Research Center 52, 123182 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.seminhematol.2023.11.006","article-title":"Biological heterogeneity in diffuse large B-cell lymphoma","volume":"60","author":"Hilton","year":"2023","journal-title":"Semin. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e70602","DOI":"10.1002\/cam4.70602","article-title":"A mitochondria-related signature in diffuse large B-cell lymphoma: Prognosis, immune and therapeutic features","volume":"14","author":"Zhou","year":"2025","journal-title":"Cancer Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: A report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: A Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.2024025652","article-title":"DLBclass: A probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma","volume":"145","author":"Chapuy","year":"2025","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1007\/s00277-024-05880-z","article-title":"Advances in biology, diagnosis and treatment of DLBCL","volume":"103","author":"Shi","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2147\/OTT.S326632","article-title":"Diffuse large B-cell lymphoma (DLBCL): Early patient management and emerging treatment options","volume":"15","author":"Vodicka","year":"2022","journal-title":"Onco Targets Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood.2023020779","article-title":"DLBCL: Who is high risk and how should treatment be optimized?","volume":"144","author":"Nowakowski","year":"2024","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e70207","DOI":"10.1002\/hem3.70207","article-title":"Large B-cell lymphoma (LBCL): EHA clinical practice guidelines for diagnosis, treatment, and follow-up","volume":"9","author":"Thieblemont","year":"2025","journal-title":"HemaSphere"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/bjh.19273","article-title":"The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology guideline","volume":"204","author":"Fox","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_13","unstructured":"Ministry of Health of Russia (2025, April 12). Clinical Guidelines for the Diagnosis and Treatment of Aggressive B Cell Lymphomas (KP129_3), (In Russian)."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse large B-cell lymphoma: R-CHOP failure\u2014What to do?","volume":"2016","author":"Coiffier","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e70006","DOI":"10.1002\/hon.70006","article-title":"Molecular features of diffuse large B-cell lymphoma associated with primary treatment resistance","volume":"43","author":"Bock","year":"2025","journal-title":"Hematol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","article-title":"Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): An open-label, randomised, phase 3 trial","volume":"20","author":"Davies","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/CM9.0000000000001294","article-title":"R-CHOP resistance in diffuse large B-cell lymphoma: Biological and molecular mechanisms","volume":"134","author":"Wang","year":"2020","journal-title":"Chin. Med. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: Clinical outcomes of the phase III intergroup trial Alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.20.01366","article-title":"ROBUST: A phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type DLBCL","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Stegemann, M., Denker, S., and Schmitt, C.A. (2022). DLBCL 1L\u2014What to expect beyond R-CHOP?. Cancers, 14.","DOI":"10.3390\/cancers14061453"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/his.15350","article-title":"Evolving molecular classification of aggressive B-cell lymphoma","volume":"86","author":"Alig","year":"2025","journal-title":"Histopathology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"84","DOI":"10.17650\/1818-8346-2024-19-4-84-92","article-title":"Personalized genotype-directed antitumor therapy for newly diagnosed diffuse large B-cell lymphoma: Efficacy and toxicity of the R-CHOP-X protocol in a single-center, non-randomized, prospective clinical trial (first results)","volume":"19","author":"Mingalimov","year":"2024","journal-title":"Oncohematology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.21320\/2500-2139-2025-18-2-177-183","article-title":"Personalized approach to treatment of newly diagnosed diffuse large B-cell lymphoma patients with respect to molecular landscape: A case report and literature review","volume":"18","author":"Mingalimov","year":"2025","journal-title":"Clin. Oncohematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ccell.2023.09.004","article-title":"Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial","volume":"41","author":"Zhang","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5045\/br.2022.2022055","article-title":"Staging and response assessment of lymphoma: A brief review of the Lugano classification and the role of FDG-PET\/CT","volume":"57","author":"Yoo","year":"2022","journal-title":"Blood Res."},{"key":"ref_27","first-page":"90","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE, version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Santana","year":"2021","journal-title":"Actas Dermosifiliogr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","article-title":"Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell\u2013like diffuse large B-cell lymphoma","volume":"35","author":"Leonard","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Thomas, C., Thapa, S., McLaughlin, C., Halloran, M., and Porcu, P. (2023). Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B-cell lymphoma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1098375"},{"key":"ref_30","first-page":"178","article-title":"Challenges and perspectives of first-line therapy in patients with diffuse B-cell lymphoma: A review","volume":"25","author":"Babicheva","year":"2023","journal-title":"J. Mod. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1200\/JCO.2023.41.16_suppl.7519","article-title":"Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit\/triple-hit lymphoma: Updated EPCORE NHL-2 data","volume":"41","author":"Falchi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_32","unstructured":"ClinicalTrials.gov (2023, November 17). A Study to Evaluate Change in Disease Activity in Subcutaneous (SC) Epcoritamab Combined with Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine and Prednisone (R-CHOP) or R-CHOP in Adult Participants with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2); ClinicalTrials.gov Identifier NCT05578976, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05578976."},{"key":"ref_33","unstructured":"ClinicalTrials.gov (2023, November 17). A Phase II Study of Glofitamab + Polatuzumab-R-CHP for Patients with High-Risk Diffuse Large B-Cell Lymphoma; ClinicalTrials.gov Identifier NCT05800366, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05800366."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): A multicenter, randomized phase III trial","volume":"36","author":"Hertenstein","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_35","unstructured":"ClinicalTrials.gov (2023, November 17). Assessing a ctDNA and PET-Oriented Therapy in Patients with DLBCL: A Multicenter, Open-Label, Phase 2 Trial; ClinicalTrials.gov Identifier NCT04604067, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04604067."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: The phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.23.00033","article-title":"Differential efficacy from the addition of bortezomib to R-CHOP in diffuse large B-cell lymphoma according to the molecular subgroup in the REMoDL-B study with a 5-year follow-up","volume":"41","author":"Davies","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","article-title":"Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL","volume":"39","author":"Wilson","year":"2021","journal-title":"Cancer Cell"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/8\/2983\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:51:14Z","timestamp":1776181874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/8\/2983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jcm15082983"],"URL":"https:\/\/doi.org\/10.3390\/jcm15082983","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]}}}